Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 17Liposarcoma 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Leiomyosarcoma 2Breast Neoplasms 2Solitary Fibrous Tumors 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Melanoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 18Ifosfamide 13Radiotherapy 8Paclitaxel 7pazopanib 6pembrolizumab 4Gemcitabine 4Filgrastim 4Chemotherapy, Adjuvant 4Bevacizumab 4spartalizumab 3durvalumab 3Sorafenib 3Propranolol 3Nivolumab 3Ipilimumab 3Imatinib Mesylate 3Etoposide 3Epirubicin 3Docetaxel 3Carboplatin 3trebananib 2regorafenib 2cixutumumab 2cemiplimab 2carotuximab 2brostallicin 2belinostat 2balstilimab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × eribulin × Sarcoma × Clear all
NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting
13 enrolled 9 charts
Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡